» Articles » PMID: 30467068

Targeting Interferon Activity to Dendritic Cells Enables in Vivo Tolerization and Protection Against EAE in Mice

Overview
Journal J Autoimmun
Date 2018 Nov 24
PMID 30467068
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Type I Interferon (IFN) is widely used for multiple sclerosis (MS) treatment, but its side effects are limiting and its mechanism of action still unknown. Furthermore, 30-50% of MS patients are unresponsive, and IFN can even induce relapses. Fundamental understanding of the cellular target(s) of IFN will help to optimize treatments by reducing side effects and separating beneficial from detrimental effects. To improve clinical systemic IFN usage, we are developing AcTaferons (Activity-on-Target IFNs = AFNs), optimized IFN-based immunocytokines that allow cell-specific targeting. In experimental autoimmune encephalitis (EAE) in mice, high dose WT mIFNα could delay disease, but caused mortality and severe hematological deficits. In contrast, AFN targeted to dendritic cells (DC, via Clec9A) protected without mortality or hematological consequences. Conversely, CD8-targeted AFN did not protect and exacerbated weight loss, indicating the presence of both protective and unfavorable IFN effects in EAE. Comparing Clec9A-, XCR1-and SiglecH-targeting, we found that targeting AFN to plasmacytoid (p) and conventional (c) DC is superior and non-toxic compared to WT mIFN. DC-targeted AFN increased pDC numbers and their tolerogenic potential, evidenced by increased TGFβ and IDO synthesis and regulatory T cell induction. In addition, both regulatory T and B cells produced significantly more immunosuppressive TGFβ and IL-10. In conclusion, specific DC-targeting of IFN activity induces a robust in vivo tolerization, efficiently protecting against EAE, without noticeable side effects. Thus, dissecting positive and negative IFN effects via cell-specific targeting may result in better and safer MS therapy and response rates.

Citing Articles

Oncostatin M: a love-hate relationship in neuroinflammation.

Hermans D, Hellings N, Broux B Neural Regen Res. 2024; 19(12):2571-2572.

PMID: 38808986 PMC: 11168498. DOI: 10.4103/NRR.NRR-D-23-02011.


A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state.

Van Lint S, Van Parys A, Van Den Eeckhout B, Vandamme N, Plaisance S, Verhee A Mol Cancer. 2023; 22(1):191.

PMID: 38031106 PMC: 10685570. DOI: 10.1186/s12943-023-01908-6.


1,25(OH)D3 Differently Modulates the Secretory Activity of IFN-DC and IL4-DC: A Study in Cells from Healthy Donors and MS Patients.

Sanseverino I, Rinaldi A, Purificato C, Cortese A, Millefiorini E, Gauzzi M Int J Mol Sci. 2023; 24(7).

PMID: 37047690 PMC: 10094841. DOI: 10.3390/ijms24076717.


Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis.

Liu C, Zhu J, Mi Y, Jin T J Neuroinflammation. 2022; 19(1):298.

PMID: 36510261 PMC: 9743681. DOI: 10.1186/s12974-022-02663-z.


Crosstalk between dendritic cells and regulatory T cells: Protective effect and therapeutic potential in multiple sclerosis.

Li R, Li H, Yang X, Hu H, Liu P, Liu H Front Immunol. 2022; 13:970508.

PMID: 36177043 PMC: 9513370. DOI: 10.3389/fimmu.2022.970508.